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Abstract: Osteoporosis is associated with increased morbidity, mortality and significant 
economic and health costs. Vitamin D is a secosteriod hormone essential for calcium 
absorption and bone mineralization which is positively associated with bone mineral 
density [BMD]. It is well-established that prolonged and severe vitamin D deficiency
 leads 
to rickets in children and osteomalacia
 in adults. Sub-optimal vitamin D status has been 
reported in many populations but it is a particular concern in older people; thus there is 
clearly a need for effective strategies to optimise bone health. A number of recent studies 
have suggested that the role of vitamin D in preventing fractures may be via its mediating 
effects on muscle function (a defect in muscle function is one of the classical signs of 
rickets) and inflammation. Studies have demonstrated that vitamin D supplementation can 
improve muscle strength which in turn contributes to a decrease in incidence of falls, one 
of the largest contributors to fracture incidence. Osteoporosis is often considered to be an 
inflammatory condition and pro-inflammatory cytokines have been associated with 
increased bone metabolism. The immunoregulatory mechanisms of vitamin D may thus 
modulate the effect of these cytokines on bone health and subsequent fracture risk. Vitamin 
D, therefore, may influence fracture risk via a number of different mechanisms.  
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1. Vitamin D Synthesis 
For the majority of the population the principle source of vitamin D is synthesis following exposure 
of the skin to UVB radiation [290–315 nm] [1]. UVB radiation acts in the upper epidermis of the skin 
with 7-dehydrocholestrol converted to pre-vitamin D3 by photolysis of the B ring structure followed 
by isomerisation [1]. These structural modifications mean that the molecule no longer conforms within 
the plasma membrane and is ejected into the extra-cellular space and drawn into the capillary beds 
where it is bound by the vitamin D binding protein [DBP] and transported to the liver [1]. Maximal 
production of vitamin D is reached after 10–15 minutes of sun exposure in summer [2] depending on 
skin pigmentation [3] and during this period one erythaema dose is achieved which is the equivalent to 
an intake of over 500µg of vitamin D3 [4]. Further UVB exposure results in the formation of in-active 
photoproducts  such as tachysterol and lumisterol that have negligible  effects on calcium   
metabolism [4] and prevent vitamin D toxicity from sun exposure.  
Geographical location is a key determinant of the efficiency of vitamin D synthesis as production is 
dependent on the angle of sunlight or the solar zenith angle [5]. As latitude increases, the amount of 
light within the wavelength range 290–315 nm to reach the earth’s surface decreases owing to an 
increased pathway of transversion and ozone absorption. Therefore, at locations above 35° latitude, the 
synthesis of vitamin D is seasonal with maximal amounts made during summer and little or no 
synthesis occurring during winter. Synthesis can also be affected by lifestyle, environmental, and 
physiological factors. Lifestyle factors such as the use of sun-screen, time spent outside and wearing of 
clothing significantly affect UVB exposure as do environmental factors such as pollution, cloud cover 
and ozone presence [6-8]. For example a sun protective factor [SPF] sunscreen of 15, if correctly 
applied, would decrease vitamin D synthesis to 1/15th or about 7% [6]. Also a recent cross-sectional 
study investigating the vitamin D status of 34 children [9–24 months old] living in a polluted area of 
Delhi reported that pollution reduced vitamin D serum concentrations by 50% [9]. Physiological 
differences such as skin complexion and age also affect synthesis: darker skin has significantly higher 
melanin content and subsequently requires a higher UVB exposure time than paler skin to synthesize 
an equivalent amount of vitamin D [10]. Increasing age is associated with a significant decrease in the 
amount of 7-dehydrocholesterol in the skin and thus, a reduction in vitamin D synthesis with studies 
reporting up to four times less cutaneous synthesis in adults aged over 70 years compared to a 20 year 
old adult [11].  
2. Dietary Sources 
Vitamin D is also obtained to a limited extent from the diet, albeit few dietary sources naturally 
contain the vitamin in sufficient quantities to make a significant contribution to requirements. The two 
main vitamin D secosteroids within the diet are vitamin D2 [ergocalciferol] and vitamin   
D3 [cholecalciferol]. Vitamin D2 is derived from plant and fungi and is produced through the 
irradiation of ergosterol. Vitamin D3, as previously mentioned, is produced from 7-dehydrocholesterol 
and is obtained in the diet from animal products with oily fish, fish oils, eggs and dairy produce 
providing the best dietary sources. A recent double blind, placebo controlled study reported that there 
is no significant difference in the effectiveness of the two isomers [12]; however it is more often Nutrients 2010, 2                                       
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reported that vitamin D3 is the more effective. This higher effectiveness of vitamin D3 over D2 is 
owing to a possible increased affinity for the vitamin D binding protein [DBP] [13,14] leading to a 
reduction in clearance of D3 and providing longer lasting concentrations of 25(OH)D in the blood than 
D2 [14].  
In relation to intakes, the composition of the habitual diet will impact on vitamin D status. For 
example, within Ireland the majority of vitamin D intakes are from sources such as meat and meat 
products [15] which contain low concentrations of the vitamin. Rich food sources such as oily fish are 
consumed infrequently. Few vitamin D fortified foods, aside from margarine, are available within 
Western Europe possibly owing to early adverse advent incidents of infantile hypercalcaemia 
attributed to over-fortification of dried milk with vitamin D [16]. Other countries, including the USA 
fortify foods; however, surveys have suggested significant differences between the actual and reported 
levels of fortification [17,18]. Vitamin D absorption occurs in the ileum and jejunum. It has been 
estimated that 75% is effectively absorbed [19] but efficiency is dependent on bile salt and micelle 
formation and, therefore, the presence of malabsorptive disorders such as Coeliac [20] or Crohn’s 
disease [21] can significantly affect absorption and thus status [22].  
3. Vitamin D Metabolism and Function [Figure 1] 
Vitamin D is bound by the DBP and transported to the liver [1]. Within the liver, the vitamin D is 
hydroxylated by 25-hydroxylase [CYP2R1] to the major circulating form of the hormone 25-
hydroxyvitamin D [25[OH]D3] [23]. Excess non-hydroxylated vitamin D is stored in the liver, adipose 
tissue and muscle [24]. The 25[OH]D, bound to the DBP, is transported to the proximal tubule cells  
of kidney. The DBP is degraded and the 25[OH]D3 is hydroxylated by 1α-hydroxylase [CYP27B1] to 
the biologically active form of the hormone, 1,25 di-hydroxyvitamin D3 [1,25[OH]2D3] [calcitriol] [25]. 
The kidney however, is not the only source of CYP27B1: it has also been detected in tissues such as 
the colon, brain and pancreas suggesting different autocrine functions of the hormone [25]. Regulation 
of CYP27B1 within the renal tubules is controlled by fibroblast growth factor [FGF-23] and by 
parathyroid hormone [PTH]. PTH stimulates while FGF-23 inhibits 1α-hydroxylase production in the 
kidney through a series of feedbacks [23,24]. Once the hormone has been metabolized it is converted 
to calcitroic acid and excreted. The primary effect of vitamin D is enhanced calcium absorption in the 
small intestine [23-25]. With hypocalcaemia, increased PTH secretion stimulates production  of 
1,25[OH]2  D3  in the kidney [25]. The hormone interacts with the vitamin D receptor  [VDR] in 
intestinal cells and complexes with the retinoic acid x receptor [RXR] in the nucleus [23,24]. This 
complex binds to the vitamin-D-responsive element [VDRE] of the calcium channel [TRPV6] which 
increases uptake of calcium into the cells and increases the absorption of calcium [24,25]. Secondly, 
within osteoblasts, vitamin D interacts with the VDR and increases the plasma membrane expression 
of the RANKL [Receptor Activator for Nuclear Factor κ B Ligand] [25]. RANK on preosteoclasts 
binds RANKL on the osteoblast which then converts the preosteoclast to an osteoclast [25]. This 
conversion releases chemicals such as hydrochloric acid to metabolise calcium stores from the bones 
into circulation to maintain the optimal physiological range [25].  
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Figure 1. Summary diagram of vitamin D metabolism and function. 
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4. Vitamin D Intake and Status 
Until recently, it was generally assumed that enough vitamin D was synthesized from sun exposure 
to meet requirements and no recommendations for dietary intakes for adults aged 18–65 yrs were set. 
However, research highlighting the effects of low vitamin D  status [26,27] has indicated the 
importance of vitamin D in the diet. Within Ireland, the Food Safety Authority for Ireland [FSAI] has 
set a wide range of 0–10 μg/d (day) for adults [28] while in the UK there is no reference nutrient intake 
[RNI] for adults [18–64 yrs], only for those over 65 yrs [10 μg/d] and pregnant and lactating women  
[10  μg/d]  [29].  In  the  US,  adequate  intakes  [AI]  are  set  at  5  μg/d  [19–50  yrs]  and  10  μg/d  
[51–70 yrs] [30] which also correspond with the WHO/FAO Expert Group recommended intakes [31].  
The difficulty in assigning a RNI for vitamin D intake is exacerbated by the current lack of 
agreement on optimal vitamin D status. While vitamin D deficiency is generally accepted as a 
25[OH]D3 serum concentration <25 nmol/L [32], the serum concentrations of 25[OH]D3 defining 
insufficiency, or optimal status are less clear. Insufficiency can be deemed as mild deficiency with a 
25[OH]D3 serum concentration <50 nmol/L [33-35]. Over extended periods of time, insufficiency has 
been associated with increased bone loss and secondary hyperparathyroidism leading to increased 
fracture risk [36]. Sufficiency has been regarded as the point at which further intakes will have no 
additional beneficial effects on PTH and calcium metabolism in regard to bone health. However, the 
cut-off values for sufficiency are still under debate. Studies have demonstrated concentrations of   
>80 nmol/L [37] or higher, 100-200 nmol/L [35], as optimal.  
As mentioned earlier, the dietary intake of vitamin D required to prevent vitamin D deficiency and 
ensure optimal vitamin D status will vary depending on sun exposure preferences. A recent study 
concluded that to maintain 25[OH]D >25 nmol/L in 97.5% of the population during wintertime the 
recommended dietary
 allowances [RDA] should be set at 8.7ug/d. However, the authors also calculated 
that a dietary intake of 12.1ug/d would be required to prevent deficiency among sun avoiders [38]. 
Such intakes are considerably higher than estimated vitamin D intakes in Ireland [3.3 µg] [39], the UK 
[4.2 µg] [40], the US [8.12 µg] [41] and other European countries [42-44].  
Vitamin D toxicity is rare [45]. The symptoms include vomiting, nausea, constipation, weight loss, 
weakness and kidney stones with subsequent hypercalcaemia and ectopic calcification of soft tissue [46]. 
However, as discussed earlier, the formation of vitamin D from sunlight is a self-limiting reaction; thus 
preventing toxicity from sun exposure. Reports of toxicity have arisen from excessive dietary intakes 
of the vitamin [17,47-49] with all such cases reporting serum 25[OH]D concentrations   
>200 nmol/L. However, severe adverse effects have only been reported with extreme intakes of 
vitamin D of 15,000 µg/d [47,48] or 42,000 µg/d [49], well above any natural intakes from food or 
supplements from clinical trials.  
5. Vitamin D and Bone Health 
Peak bone mass is attained by the third decade of life [50] with genetics, physical activity, nutrition 
and lifestyle factors [51,52] playing key roles in the accumulation and maintenance of bone. Age 
related bone loss occurs around the fourth decade [53], resulting in a gradual decline of BMD though 
this process is accelerated in females during and up to 10 years post-menopause owing to possible Nutrients 2010, 2                                       
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oestrogen deficiency derived bone loss [54]. The development of bone disease in later life is related to 
the attainment of maximum peak bone mass and the maintenance of bone mass in adulthood [55]. In 
relation to vitamin D, research has shown that inadequate vitamin D intakes over long periods of time 
can lead to bone demineralization [56]. Vitamin D deficiency leads to decreased calcium absorption 
and ultimately the release of calcium from the bones in order to maintain circulating calcium 
concentrations [56]. Continuous bone turnover and resorption weakens the architecture of bones and 
increases fracture risk via secondary hyperparathyroidism [56] ultimately leading to the development 
of osteomalacia and osteoporosis. Osteoporosis is clinically defined as a BMD 2.5 standard deviations 
below the mean of healthy young individuals [57,58].  
There is a direct relationship between BMD and fracture risk [59], with a decrease in bone strength 
and density associated with an increased incidence rate of fractures [60]. Fractures usually occur at the 
hip, spine and wrist [61] and not only carry considerable health costs, but can also result in increased 
mortality and a decreased quality of life [62-64]. Fracture incidence has been shown to increase with 
age [65]; therefore it has been imperative to develop preventive strategies in order to minimize the 
development of this condition. Given the relationship between vitamin D and bone mineralization, 
optimal vitamin D status is essential for minimization of fracture risk.  
6. Fracture Risk  
A number of studies have investigated the effects of vitamin D or vitamin D in combination with 
calcium on fracture incidence (Tables 1–3). Three intervention trials of vitamin D alone [66,75,77] 
have reported a significant reduction in fracture occurrence. For example, one study [75] reported a 
33% lower rate for fracture and a 22% lower rate for first fracture at any site compared to placebo in 
free-living individuals with 100,000 IU D3. While in another intervention [66], which supplemented 
with 150,000–300,000 IU D2, an apparent significant fracture reduction from baseline was reported, 
especially in the upper limb both in free-living and institutionalized subjects [though this study had no 
placebo and was not blinded]. Furthermore, in a trial [77] supplementing post-stroke elderly patients 
with 1000 IU D2, zero hip fractures were reported in the vitamin D arm (n = 48). These results are also 
supported by trials with vitamin D in combination with calcium. For example, in one study [89], 
supplementation with 400 IU D3 and calcium resulted in a reduction in the fracture incidence rate of 
community dwelling individuals. Furthermore, another trial [81] reported a significant reduction in hip 
fractures among institutionalized elderly females supplemented with calcium and vitamin D3 for two 
years. A subsequent analysis of the same cohort after 42 months supplementation indicated that hip 
fractures and non-vertebral fractures remained lower in the treatment group [94]. However, not all 
trials of vitamin D or vitamin D in combination with calcium have reported significant effects. For 
example, Lyons et al. [79] in a double-blinded, placebo-controlled trial, supplemented nursing home 
residents with 100,000 I.U D2 quarterly for five years and reported no significant reduction in 
fractures. Moreover, in a much larger trial [92] of 36,000 subjects with 400 IU D3 & 500 mg calcium 
no significant reduction in fractures was reported. The difference in outcomes between trials is difficult 
to explain, albeit there are a number of possible explanations for lack of reported effects. A large 
number of trials [69,71,74,76,85,87,88,91-93] have supplemented with between 300–800 IU vitamin D 
which may not be enough to exert a beneficial effect according to a recent meta-analysis [95,96]. In Nutrients 2010, 2                                       
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addition, studies which have documented significant fracture reductions have reported that effects may 
be more evident among institutionalized elderly people compared to free-living individuals.  
These observations are supported by a number of meta-analyses. Bischoff-Ferrari (2005) conducted 
a meta-analysis [97] of 7 RCTs and concluded vitamin D in the range of 700–800 IU/d reduced the 
risk of hip/non-vertebral fractures by 25% while a calcium intake of more than 700 mg/d was required 
for non-vertebral fracture prevention. In a separate analysis [98], an 18% reduction in hip fracture risk 
and a significant reduction in non-vertebral fractures were achieved with vitamin D and calcium 
supplementation. It has also been reported that vitamin D and calcium intervention is more effective in 
reducing the risk of hip fracture in patients in institutionalized care compared to free living individuals 
in the community [94,95] with more than 800 IU vitamin D and more than 1200 mg calcium daily 
required respectively to exert a beneficial effect. In keeping with this finding of a threshold effect of 
vitamin D, a more recent analysis [99] concluded that supplementation with 400 IU/d or less was 
ineffective while doses between 482–770 IU/d reduced fractures [hip 18%, non-vertebral 20%] with no 
further effect with additional calcium supplementation.  Conversely, a recent Cochrane analysis 
concluded that vitamin D alone did not have a significant effect on fracture prevention and was only 
effective when combined with calcium in institutionalized individuals [100]. This finding is supported 
by a recent pooled analysis of over 68,000 patients which reported that 400–800 IU/d of vitamin D 
alone was not effective but 400 IU/d combined with calcium reduced the rate of hip fracture by 16% 
and reduced overall fractures by 8% [101]. Two meta-analyses to date [99,102,] have looked at the 
effect of vitamin D analogues with one concluding that calcitriol & alfacalcidol were more effective at 
reducing fracture risk than D2 or D3 [102]. The use of such analogues, however, is not widely 
advocated at present given the potential risks and cost implications associated with them [99]. 
Taken together, the results from the meta-analyses support a cause and effect relationship between 
vitamin D in combination with calcium in the reduction of risk of vertebral and non-vertebral 
osteoporotic fractures. Several mechanisms may underlie this positive association between vitamin D 
and fracture risk including the well documented beneficial effects of vitamin D on bone mineral 
density.Nutrients 2010, 2                                       
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Table 1. Intervention  with vitamin D on fracture prevention. 
Study  Study  n  Sex  Mean age  Treatment  Length  Results 
   design         [years]          
               
Heikinheimo et al. 1992 (66)  CT  320   M/F  75–84  150,000–300,000 IU D2 yrly  5 yrs  Groups with vitamin D had sig lower rate of fractures,  
    479   M/F  >85  150,000–300,000 IU D2 yrly  5 yrs  particularly upper limb but not lower limb fractures 
Lips et al. 1996 (69)  CT  2578   M/F  80  400 IU D3/d  3.5 yrs  No effect  
Peacock et al. 2000 (71)  CT  438   M/F  74  800 IU D3/d  4 yrs  No effect 
Meyer et al. 2002 (74)  CT  1144   M/F  84  400 IU D3/d  2 yrs  No effect  
Trivedi et al. 2003 (75)  CT  2686   M/F  75  100 000 IU D3 four monthly   5 yrs  33% lower rate for fracture at hip,forearm and vertebrae 
Grant et al. 2005 (76)  CT  2675   M/F  77  800 IU D3/d  2 yrs  No effect 
Sato et al. 2005 (77)  CT  96   F  74  1, 000 IU D2/d  2 yrs  Reduction in hip fracture 
Law et al. 2006 (78)  OSD  3717   M/F  85  1,100 IU D2/d  10mths  No effect 
Lyons et al. 2006 (79)  CT  3440   M/F  84  100 000 IU D2 four monthly  3 yrs  No effect 
Smith et al. 2007 (80)  CT  9440   M/F  79  300 000 IU D2/d  3 yrs  No effect 
CT, controlled trial; OSD, open study design trial; F, female; M, male; D3, cholecalciferol; D2, ergocalciferol; Ca, calcium; /d, daily; mths, months; yrly, yearly; 
IU, International units 
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Table 2. Interventionwith vitamin D plus calcium on fracture prevention. 
Study  Study  n  Sex  Mean age   Treatment  Length  Results 
   design           [years]          
               
Chapuy et al. 1992 (81)  CT  3270   F  84  800 IU D3 & 1200 mg Ca/d  2 yrs  Hip fractures 43% & non-vertebral fractures 32% lower 
 
CT  389   M/F  71  700 IU D3 & 500 mg Ca/d  3 yrs  Reduction in non-vertebral fractures  Dawson Hughes et al. 1997 (84) 
Komulainen et al. 1999 (85)  CT  464   F  52  300 IU D3 (100 IU in last yr) & 93 mg Ca/d  5 yrs  No effect 
Chapuy et al. 2002 (87)  CT  583   F  85  800 IU D3 & 1200 mg Ca/d  2 yrs  No effect 
Harwood et al. 2004 (88)  OSD  76   F  82  800 IU D3 & 1000 mg Ca/d  1 yr  No effect  
Larsen et al. 2004 (89)  CT  9605   M/F  74  400 IU D3 & 1000 mg Ca/d  3 yrs  16% reduction in fracture risk 
Flicker et al. 2005 (90)  CT  625   M/F  83  10,000 IU D2 wk to 1000  2 yrs  No effect  
          IU/d & 600 mg Ca/d     
 
OSD  3314  F  70  800 IU D3 & 1000 mg Ca/d  25mths  No effect  Porthouse et al. 2005 (91) 
Grant et al. 2005 (76)  CT  2638   M/F  77  800 IU D3 & 1000 mg Ca/d  2 yrs  No effect 
 
CT  36282  F  62  400 IU D3 & 500 mg Ca/d  7 yrs  No effect  Jackson et al. 2006 (92) 
Pfeifer et al. 2009 (93)  CT  242   M/F  77  800 IU D3/1000 mg Ca/d  2 yrs  No effect 
CT, controlled trial; OSD, open study design trial; F, female; M, male; D3, cholecalciferol; D2, ergocalciferol; Ca, calcium; /d, daily; yr, year; yrs, years 
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Table 3. Intervention with vitamin D analogues (with / without calcium) on fracture incidence. 
Study  Study  n  Sex  Mean age  Treatment  Length  Results 
   design        (years)          
Vitamin D analogues                 
Hayashi et al. 1992 (67)  CT  740   M/F  75  40 IU Ac/d  1 yr  Lower fracture incidence 
 
CT  622   F  63  20 IU Cl/d  3 yrs  Reduction in vertebral fractures  Tyliard et al. 1992 (68) 
Sato et al. 1999 (70)  CT  86   M/F  70  40 IU Ac/d  2 yrs  17.5% lower fracture rate 
 
CT  41   M  57.5  20 IU Cl/d  2 yrs  No effect   Ebeling et al. 2001 (72) 
 
CT  489   F  72  20 IU Cl/d  2 yrs  No effect   Gallagher et al. 2001 (73) 
               
Vitamin D analogues  
with calcium               
 
CT  80   F  70  40 IU Ac & 300mg Ca/d  1 yr  Decreased vertebral fracture incidence  Orimo et al. 1994 (82) 
 
CT  113   F  70  30 IU Ac & 300mg Ca/d  2 yrs  Decreased incidence of fractures  Shikari et al. 1996 (83) 
Stempfle et al. 1999 (86)  CT  132   M/F  50  10 IU Cl & 1000mg Ca/d  3 yrs  No effect 
CT, controlled trial; F, female; M, male; Cl, Calcitriol; Ac, Alfacalcidol; Ca, Calcium; /d, daily; wkly, weekly; yr, 
year;yrs, years 
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7. Vitamin D and BMD 
A number of cross-sectional studies have investigated the relationship between vitamin D status and 
BMD. For example, one study [103] of middle aged women reported that serum concentrations of 
25[OH]D were positively related to bone density of the lumbar spine, neck and trochanteric regions of 
the femur. In addition, a more recent study [104] reported a positive association of vitamin D and 
BMD and suggested the effect may be even greater in the 90–100 nmol/L serum range of vitamin D. 
Given the observed relationship between vitamin D status and BMD, a large number of intervention 
studies have investigated the effects of vitamin D alone or vitamin D in combination with calcium on 
BMD (Tables 4–5). 
Vitamin D alone and in combination with calcium appears to have a clear significant effect on 
BMD. For example, 5 out of 9 studies of vitamin D alone [70,73,105-107], plus 16 of 22   
studies [81,84,88,92,94,98,110-112,116-118,120,122] of vitamin D in combination with calcium have 
reported significant positive effects on BMD. For example, in supplementation with vitamin D alone, 
one study [107] reported a significant benefit after only five weeks in participants with impaired 
vitamin D status and osteoporosis/osteopenia. Supplementation with 100 000 IU D2 resulted in rapid 
improvement in vitamin D status and significant improvement in spinal and the femoral neck BMD. 
The findings are supported by another trial [106] of over 300 elderly mobile females in whom two 
years of vitamin D3 supplementation resulted in significant improvements in BMD. The improvements 
in BMD can also be seen in the trials with vitamin D and calcium. Over the last 20 years, 14 
intervention studies examining the effect of vitamin D and calcium supplementation on BMD have 
been published. Overall, positive results have been reported, with doses more than 400 IU associated 
with significant effects on bone heath. However, the optimal dosage of vitamin D remains unclear. For 
example, two trials [117,120] which supplemented with 560 IU D3 & 1000 mg calcium/d [117] or 560 
IU D3 and 500 mg Ca/d [120] reported increases in lumbar spine BMD while conversely; another  
trial [115] supplementing with 500 IU D3 and 1000 mg calcium/d over the same intervention period 
reported no significant effect. Four trials have reported significant increases in BMD with   
700 IU [84,112] to 800 IU [81,88] D3 and calcium [500–1,200 mg]; however, in a study that 
supplemented African-American females with 800 IU D3 and 1,200–1,500mg of calcium [121] no 
significant effects were reported. The findings in African-American females could be explained, in 
part, by lower bone remodelling rates [124] and enhanced skeletal resistance to the effects of   
PTH [125] in this population group. Studies intervening with higher doses of vitamin D have also 
produced conflicting results. For example, one trial [120], supplementing with 1428 IU D2 and 1000 
mg calcium/d reported no effect while another [123] supplementing 5000 IU D3/d with 320mg 
calcium reported significant effects. In the latter trial, 45 elderly participants were supplemented with 
vitamin D3 through bread fortification. An impressive 4% increase in spine and 23.4% in hip BMD 
were reported. Trials (Table 5) supplementing with vitamin D analogues have also reported significant 
improvements in BMD. For example, in one trial [73], 20 IU alone resulted in a significant increase in 
spine BMD. Trials [98,99,111,116,118,119] with vitamin D analogues and calcium have also reported 
consistent results with the majority reporting significant improvements in   
BMD [70,73,98-99,111,116,118-119].  
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In summary, the majority of vitamin D supplementation trials demonstrate a positive effect of the 
vitamin on BMD and in de facto fracture incidence although further studies are required to confirm the 
optimal dose of vitamin D associated with these benefits. Moreover, although the potential benefits of 
vitamin D on fracture incidence may be at least partly attributed to beneficial effects on BMD, vitamin 
D may also impart advantages by reducing fracture occurrence through other mechanisms. One such 
mechanism is based on the potential of vitamin D to enhance muscle strength and thereby decrease the 
risk of falls. 
8. Vitamin D and Muscle Strength 
A recent review [126] concluded that falls were the biggest contributor to fractures and 
observational studies have reported that vitamin D deficiency is associated with muscle   
weakness [127] and an increased pre-disposition for falling [128]. Such associations are not surprising 
given that research has shown that the VDR is expressed in both skeletal muscle [129] and myoblast 
cells [130]. In vitro evidence has demonstrated that vitamin D can increase protein synthesis and 
cellular growth in muscle cells with an increase in size and number of type 2 muscle fibres [131] 
which are of particular importance as these are the first muscle fibres recruited when falling [132]. In 
support of these findings, a recent observational study [133] has reported vitamin D plasma 
concentrations in the range of 40-90nmol/L was associated with improved musculoskeletal function 
than serum concentrations <40nmol/L. Additionally, another study [134] has suggested that impaired 
muscle function in vitamin D deficient subjects could be present even before indications of bone 
disease have been recognised Such evidence clearly provides a mechanism to support an improvement 
in muscle strength and in defacto bone health following vitamin D supplementation. 
A number of intervention trials have investigated the effects of vitamin D supplementation on 
muscle with contrasting results. One of the earliest supplementation studies reported that 40 IU 
alfacalcidol administered over a period of between 3 and 6 months increased the size and number of 
type 2 muscle fibres [131]; however, a subsequent study using a lower dose [20 IU alfacalcidol] for 
three years reported no effect of supplementation on muscle strength [135]. In the later study, baseline 
vitamin D status was reported at 60nmol/L, potentially reducing any likely beneficial effect of 
supplementation. Furthermore, a single 300,000 IU dose of vitamin D3 failed to exert a beneficial 
effect in frail elderly individuals, even in those deficient in vitamin D [136]. In contrast,   
Sato et al. [77] reported that daily supplementation with 1000 IU vitamin D2 for two years produced a 
significant increase in type 2 muscle fibre diameter in hospitalized elderly females with post-stroke 
hemiplegia. More recently, two studies have reported significant associations with vitamin D and 
muscle strength [137,138] with one study reporting a significant association between vitamin D and 
lower extremity function. The observed beneficial effects of vitamin D on muscle could be explained 
by its modulating effects on PTH as hyperparathyroidism has been reported to induce muscle 
weakness and atrophy of type 2 muscle fibres in animal models [139]. The observations, in turn, could 
be explained by the promoting effects of PTH on pro-inflammatory cytokines [140], which are often 
considered co-factors for muscle wasting and disability, especially in older individuals [141]. For 
example, PTH has been shown to increase production of IL-6 in vivo [140], which has been linked 
with muscle weakness and bone resorption. Nutrients 2010, 2                                       
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Table 4. Intervention with vitamin D (with / without calcium) on bone mineral density (BMD). 
Study  Study  n  Sex  Mean age  Treatment  Length  Results 
   design        (years)          
Vitamin D                
Nordin et al. 1985 (105)   CT  109   F   65-74  15,000 IU D2 wkly  2 yrs  Reduced rate of metacarpal cortical bone loss  
Ooms et al. 1995 (106)   CT  348   F  80  400 IU D3/d  2 yrs  Inc. in BMD; femoral neck; 1.9% in left, 2.6% in right 
Adams et al. 1999 (107)   IT  12   F  60  100 000 IU D2/wkly  5 weeks  Inc. in BMD; femoral neck (4.9%) & spine (4.1%) 
Hunter et al. 2000 (108)   CT  128   F  58.7  800 IU D3/d  2 yrs  No effect  
Peacock et al. 2000 (71)  CT  438  M/F  74  800 IU D3/d  4 yrs  No effect  
Patel et al. 2001(109)   CT  70   F  47.2  800 IU D3/d  2 yrs  No effect  
 
              Vitamin D with calcium 
Dawson Hughes et al. 1991(110)  CT  249   F  81  400 IU D3 & 377 mg Ca/d  1 yr  Reduced winter time bone loss/improved BMD of spine 
Chapuy et al. 1992 (81)  CT  3270   F  84  800 IU D3 & 1200 mg Ca/d  2 yrs  BMD of femur increased by 2.7% compared to placebo 
Dawson Hughes et al. 1995 (112)  CT  247   F  63   700 IU D3 & 500 mg Ca/d  3 yrs  1.5% inc. in BMD in femoral neck in 700 IU group only 
Adachi et al. 1995 (113)   CT  62  M/F  64  7142 IU D3 & 1000 mg Ca/d  35mths  No effect 
Bernstein et al. 1996 (114)   CT  24  M/F  35  250 IU D3 & 1000 mg Ca/d  1yr  No effect 
Buckley et al. 1996 (115)   CT  66  M/F  52  500 IU D3 & 1000 mg Ca/d  2 yrs  No effect  
DawsonHughes et al. 1997 (84)  CT  389  M/F  71  700 IU D3 & 500 mg Ca/d  3 yrs  Inc. in BMD 
Baeksgaard et al. 1998(117)   CT  240   F  62.5  560 IU D3 & 1000 mg Ca/d  2 yrs  1.6% inc. in lumbar spine BMD 
Komulainen et al. 1999 (85)  RT  464   F  52  300 IU C/c/d (100IU D3/d   5 yrs  No effect  
          5th year) & 93 mg Ca/d     
Cooper et al. 2003(120)   CT  187   F  56  1,428 IU D2 & 1000 mg Ca/d  2 yrs  No effect  
Meier et al. 2004 (121)   OSD  55  M/F  56  500 IU D3 & 500 mg Ca/d  2 yrs  0.8 % inc. in lumbar spine BMD 
Harwood et al. 2004 (88)  OSD  76   F  82  800IU D3 & 1000 mg Ca/d  1 yr  Change in Hip BMD  
Aloia et al. 2005 (122)   CT  280   F   50-75  800 IU D3/d (2000IU after 2yrs) 3 yrs  No effect  
Jackson et al. 2006 (92)  CT  36282   F  62  400 IU D3 & 500 mg Ca/d  7 yrs  Change in Hip BMD (+1.06% compared to placebo) 
Mocanu et al. 2009 (123)   SAD  45  M/F  71  5000 IU D3/d & 320 mg Ca/d  1 yr  4% inc. lumbar spine & 23.4% inc. hip BMD 
CT, controlled trial; SAD, single arm den; OSD, open study design; F, female; M, male; D3, cholecalciferol; D2, ergocalciferol; Ca, calcium; /d, daily; wkly, weekly; mths, months; 
Inc., increase yr, year; yrs, years       *added calcium supplements to ensure intakes were 1200–1500 mg/d Nutrients 2010, 2                                       
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Table 5. Intervention with vitamin D analogues (with / without calcium) on BMD. 
Study  Study  n  Sex  Mean age  Treatment  Length  Results 
   design        (years)          
Vitamin D analogues               
Sato et al. 1999 (70)  CT  86   M/F  70  40 IU Ac/d  2 yrs  Decreased loss of BMD compared to placebo 
Ebeling et al. 2001 (72)  CT  41   M  57.5  20 IU Cl/d  2 yrs  No effect 
Gallagher et al. 2001 (73)  CT  489   F  72  20 IU Cl/d  2 yrs  Increase in spine BMD 
               
Vitamin D analogues  
with calcium               
Sambrook et al. 1993 (111)  CT  103   M/F  46  24 IU Cl & 1000 mg Ca/d  1 yr  Reduced corticosteroid bone loss in the lumbar spine. 
 
CT  80   F  70  40 IU Ac & 300 mg Ca/d  1 yr  Increase in lumbar spine (L2-L4) BMD in 0.65%  Orimo et al. 1994 (98) 
 
CT  113   F  70  30 IU Ac & 300 mg Ca/d  2 yrs  Increase in lumbar spine (L2-L4) BMD (1.81–2.32%)  Shikari et al. 1996 (99) 
Sato et al. 1997 (116)   CT  64   M/F  68  40 IU Cl & 300 mg Ca/d  6 mths  Improvement in BMD on intact side of stroke subjects 
 
CT  81   F  31  20 IU Cl & 1200 mg Ca/d  2 yrs  Increase in BMD at lumber spine 
Lambrinoudaki  et al. 1999 
(118) 
Stempfle et al. 1999 (86)  CT  132   M/F  50  10 IU Cl & 1000 mg Ca/d  3 yrs  No effect 
Sambrook et al. 2000 (119)   CT  65   M/F  46 
20-30  IU Cc & 600 mg 
Ca/d  2 yrs  Reduced bone loss in proximal femur 
CT, controlled trial; F, female; M, male; Cl, Calcitriol; Ac, Alfacalcidol; Ca, Calcium; /d, daily; wkly, weekly; mths, months; yr, year; yrs, years 
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Therefore, though studies to date have been conflicting, vitamin D supplementation has the 
potential to positively benefit muscle function which could subsequently lead to a decreased propensity 
to fall and fracture.  
9. Falls and Vitamin D 
Given the potential for vitamin D to modulate muscle strength, it is perhaps not surprising that a 
large number of studies which have investigated the effects of intervention with vitamin D alone or in 
combination with calcium on risk of falls [Tables 6-7]. Of six trials that have supplemented with 
vitamin D alone, two [77,143] have reported significant reductions in fall rate following 
supplementation with vitamin D at 1000 or 800IU of vitamin D2/d respectively. Importantly, however, 
seven out of nine studies [89,144-149] that supplemented with vitamin D in combination with calcium 
have reported significant reductions in falls. Therefore, as with fracture prevention, vitamin D appears 
to be more effective in reducing the risk of falls when used in combination with calcium. Significantly, 
one meta-analysis of 5 RCTs [150] concluded that vitamin D reduced the risk of falling by 22% while 
another more recent meta-analysis [151] of eight RCTs concluded that supplementation with vitamin D 
in the region of 700–1,000 IU/d reduced falls by 19% with doses below this level ineffective. It has 
been suggested that vitamin D supplementation exerts greater effects on institutionalized versus free-
living individuals [145], a finding which may be explained by a number of factors. Individuals in care 
typically have lower serum concentrations of vitamin D compared to free-living individuals [152] 
leaving them pre-disposed to muscle weakness and increased risk of falling and also more likely to 
benefit from supplementation. Furthermore, compliance with the supplementations regimen may be 
better among institutionalised individuals where supplements are provided by caregivers. Nevertheless, 
not all trials of institutionalized individuals have produced significant findings [78].  
In summary, based on the evidence reported, vitamin D, particularly when supplemented with 
calcium, can have a beneficial effect on the prevention of falls and thus fractures.  
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Table 6. Intervention with vitamin D or vitamin D analogues on falls. 
Study 
Study 
design  n  Sex 
Mean age 
Treatment  Duration  Results  (years) 
               
               
Graafmans et al. 1996 (142)  CT  354   M/F   >70  400 IU D3/d (2 yrs)  7 mths  No effect on falls 
Sato et al. 1999 (70)   CT  86   M/F  70  40 IU Ac/d  2 yrs  No effect on falls 
 
CT  243   M/F  79  300,000 IU D3 once  6 mths  No effect on falls  Latham et al. 2002 (136) 
Trivedi et al. 2003 (75)   CT  2686   M/F  75  100,000 IU D3 quartley  5 yrs  No effect on falls 
Sato et al. 2005 (77)  CT  96   F  74  1,000 IU D2/d   2 yrs  59% reduction in falls and increase in size/number type 2 muscle 
Law et al. 2006 (78)   OSD  3717   M/F  85  1,100 IU D2/d  10 mths  No effect 
Broe et al. 2007 (143)   CT  124   M/F  89  800 IU D2/d  5 mths  72% lower fall rate 
CT, controlled trial; F, female; M, male; D3, cholecalciferol; D2, ergocalciferol; Ac, Alfacalcidol /d, daily; wkly, weekly; Ca, calcium; 
 
 
 
 
 
 
 
   Nutrients 2010, 2                                       
 
 
709 
Table 7. Intervention with vitamin D or vitamin D analogues (with / without calcium) on falls. 
Study 
       Study 
design  n  Sex 
Mean age 
Treatment  Duration  Results  (years) 
               
DawsonHughes et al. 1997 (84)  CT  389   M/F   >65   700 IU D3/ 500 mg Ca/d  3 yrs  No effect on falls 
 
CT  148   F   70–86  800 IU D3/1,200 mg Ca/d  2 mths  Reduced body sway (9%) and 1 yr follow up lower number of falls   Pfeifer et al. 2000 (144) 
 
CT  583   F  85  800IU D3/1200 mg Ca/d  2 yrs  No effects on falls  Chapuy et al. 2002 (87)  
 
IT  5771   F  74  400 IU D3/1000 mg Ca/d  3.5yrs  Reduced risk of severe falling by 12%  Larsen et al. 2002 (89) 
 
CT  122   F   >65  800IU D3/1200 mg Ca/d  12 wks  49% reduction in falling and improved muscoskeletal function   Bischoff et al.2003 (145)  
Dukas et al. 2004(146)   CT  378   M/F  75  40 IU Ac/d  9 mths  Reduction in falls only with Ca intake >512 mg/d in addition 
Flicker et al. 2005 (147)   CT  625   M/F  83  10,000 IU D2/wkly*   2 yrs  Reduction in incidence ratio for falls 
Bischoff et al. 2006 (148)   CT  445   M/F   >65  700 IU D3/500 mg Ca/d  3 yrs  46% reduction falls in womem (65% reduction in non-active women)  
Pfeifer et al. 2009 (149)   CT  242   M/F   >70  800 IU D3/1000mg Ca/d  18 mths  27% reduction in falls & 28% decrease in body sway 
CT, controlled trial; F, female; M, male; D3, cholecalciferol; D2, ergocalciferol; Ac, Alfacalcidol /d, daily; wkly, weekly; Ca, calcium; *changed to 1000 IU D2 daily with 600 mg calcium Nutrients 2010, 2                                       
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10. Bone Health, Vitamin D and Inflammation 
Increasing age is not only associated with a decrease in BMD and muscle strength but is also 
associated with marked changes in immune and inflammatory responses. Studies conducted 
predominantly in individuals >70 y of age have demonstrated that, while the most striking age-related 
changes have been observed in the cell-mediated arm of the immune system, age-associated 
restructuring of the immune system is a consequence of alterations in virtually all of its components. 
These alterations result in the up-regulation of some components of the immune system as well as 
diminished function of others [153,154].  Changes include decreased mature lymphocyte function, 
decreased replication of hematopoietic cells [153] and an up-regulation in the production of pro-
inflammatory cytokines such as interleukin 6 [IL-6] and tumour necrosis factor-alpha [TNF-α] [154].  
Inflammation is considered a characteristic of osteoporosis [155] and research has focused on the 
effects of cytokines on bone metabolism [156]. The cytokines IL-1, IL-6 and TNF-α have been shown 
to regulate bone [157] and evidence from animal models has suggested that these cytokines are 
associated with the development of osteoporosis [154,155] through stimulation of osteoclastogenesis 
and subsequent bone resorption [158].  In  vitro  studies have indicated that TNF-α  and  IL-1 can 
stimulate human osteoclastic bone resorption [159], possibly owing to increased RANKL expression in 
a synergistic relationship; with TNF-α  depending  on  the  presence  of  IL-1 for optimal osteoclast 
formation [160].  
To date, of the pro-inflammatory markers related to bone, the most studied is IL-6, the production 
of which can be stimulated by PTH [161]. However, findings from in vitro  studies have been 
inconsistent, with reports that IL-6 stimulates both bone formation [162] and resorption [163]. Human 
studies have also produced inconsistent results on the relationship between IL-6 and bone health. A 
recent longitudinal study [164], reported that baseline IL-6 and change in IL-6 over a period of   
2.9 years were consistently associated with bone loss in elderly adults. These findings are supported by 
a similar study in post-menopausal women [165]. Two other cross-sectional studies found no 
significant association between IL-6 and BMD [166,167] and another longitudinal study reported a 
positive association between IL-6 and bone loss in the lumbar spine [168]. The associations between 
other cytokines and bone health have also been assessed; TNF-α  is  associated  with  bone 
resorption [169], as is IL-17, which is reported to act synergistically with TNF-α to promote bone 
turnover in rheumatoid arthritis patients [170]. Conversely, some animal studies have suggested that 
IL-17 is protective in oestrogen-derived bone loss which commonly occurs during the 
menopause [171].  
The relationship between polymorphisms in cytokine genes, which alter expression of the particular 
cytokine, and bone health has been investigated with varying results. Polymorphisms in the IL-1 
receptor antagonist [IL-1ra] gene in post-menopausal women have been associated with lower BMD 
and increased fracture risk [172,173]; however, such associations with this polymorphism are not 
evident in all trials [174]. Other polymorphisms that have been identified include the 174 GG 
polymorphism in IL-6; this polymorphism results in a higher expression of IL-6 protein and has been 
associated with increased bone resorption [175]. This particular polymorphism has also been reported 
as a potential risk factor for hip fracture among late postmenopausal women without oestrogen Nutrients 2010, 2                                       
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replacement therapy and those with inadequate calcium intakes [176]. Studies have also indicated that 
polymorphisms in the TNFRSF1B gene, which codes for a TNF receptor, also contain polymorphisms 
which show associations with BMD [177,178]. This relationship between bone and cytokines is further 
strengthened by another study which reported that a polymorphism in transforming growth factor 
[TGF]-β1 is associated with increased bone mass and is less common in individuals with osteoporotic 
fractures [173].  
Evidence from both epidemiological and observational studies has  highlighted the 
immunoregulatory effects of vitamin D; research suggesting a potential role for the vitamin in the 
management of immunological disorders such as multiple sclerosis [179] and rheumatoid arthritis [180]. 
The VDR are located in of a variety of immune cells, including monocytes and macrophages [181]. 
Following binding of 1,25 [OH]2D to the VDR, monocyte and macrophage activity is up regulated 
enhancing the host defences and an immunosuppressive effect is observed in lymphocytes decreasing 
the activity of T and B cells [182]. A number of studies have reported that vitamin D, in the form of 
1,25[OH]2D3, can down regulate cytokine production. For example, in vitro studies have reported a 
significant decrease in IL-6 and TNF-α with vitamin D [183,184]. In vivo studies have also reported 
positive associations. For example, Zhu et al [185] investigated an animal model of inflammatory 
bowel disease and reported that vitamin D, in the form of 1,25[OH]2D, downgraded the production of 
TNF-α.  This  finding  is  supported  by  other  studies  investigating  clinical  populations  which  have 
reported positive effects of vitamin D supplementation on cytokine profiles in patients with congestive 
heart failure [186] and multiple sclerosis [187]. Moreover, in relation to bone health, one study has 
investigated the potential of vitamin D to alter cytokine production in individuals at increased risk of 
fracture and concluded that 20 IU/day of calcitriol for 6 months decreased both IL-1  and TNF-α 
concentrations and increased BMD in post-menopausal women with osteoporosis [188]. 
In summary, while not assessed in the majority of vitamin D intervention studies to date, it is 
possible given the immunoregulatory effects of vitamin D together with the reported inflammatory 
aetiology of osteoporosis, that the beneficial effects of vitamin D on fracture risk may be mediated, at 
least in part, by an effect of vitamin D on cytokine concentration. Clearly there is a need for more 
studies, both observational and intervention studies, to determine whether vitamin D status favourably 
modulates bone health through an effect on the immune and inflammatory systems. 
11. Conclusions  
It is clear that vitamin D is essential for bone health; with insufficient intakes resulting not only in 
the classical deficiency diseases of rickets and osteomalacia but also in increased bone metabolism and 
enhanced fracture risk. With evidence accumulating of inadequate vitamin D status in many countries 
worldwide and particularly in older people, who represent an ever increasing section of the population, 
maintaining bone health and decreasing fracture risk is set to become an even greater economic and 
social challenge over the coming decades. The evidence from research findings to-date indicates that 
supplementation with vitamin D in those most at-risk of impaired bone health (immobile or 
institutionalized elderly) has a beneficial effect on fracture prevention. Research clearly suggests 
vitamin D not only improves BMD but also enhances muscle function leading to a decreased number 
of falls and has the potential to modulate the effect of pro-inflammatory cytokines on bone Nutrients 2010, 2                                       
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metabolism. The level of supplementation required for an optimal effect on fracture prevention, 
however, is still under debate with multiple studies indicating different dosage regimens. The majority 
of trials and meta-analyses indicate that a dose of vitamin D of 800 IU/d in combination with a 
sufficient intake of calcium is optimal, albeit some studies suggest an even greater benefit at higher 
intakes. Further studies are required to confirm the optimal dose of vitamin D required to reduce 
fracture risk in older people. In addition, further research is warranted in order to explore the emerging 
and potentially exciting effect of vitamin D on pro-inflammatory cytokines and bone health.  
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